DERM vs. XERS, MGNX, EPIX, RVNC, INZY, CRMD, AQST, ATAI, ENTA, and XBIT
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Xeris Biopharma (XERS), MacroGenics (MGNX), ESSA Pharma (EPIX), Revance Therapeutics (RVNC), Inozyme Pharma (INZY), CorMedix (CRMD), Aquestive Therapeutics (AQST), Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry.
Journey Medical (NASDAQ:DERM) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
Xeris Biopharma received 140 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 69.80% of users gave Xeris Biopharma an outperform vote.
Journey Medical currently has a consensus target price of $8.50, indicating a potential upside of 117.95%. Xeris Biopharma has a consensus target price of $4.63, indicating a potential upside of 105.10%. Given Journey Medical's higher possible upside, analysts plainly believe Journey Medical is more favorable than Xeris Biopharma.
Journey Medical has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 19.4% of Journey Medical shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Journey Medical has higher earnings, but lower revenue than Xeris Biopharma. Journey Medical is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Journey Medical has a net margin of -5.20% compared to Xeris Biopharma's net margin of -37.58%. Journey Medical's return on equity of -32.83% beat Xeris Biopharma's return on equity.
In the previous week, Journey Medical had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 6 mentions for Journey Medical and 5 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.49 beat Journey Medical's score of 0.48 indicating that Xeris Biopharma is being referred to more favorably in the news media.
Summary
Journey Medical beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
